

Study: ENGOT-en20 / XPORT-EC

A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

MaNGO Sites:

Prov.	City	Site	Principal Investigator	Active **
BS	Brescia	Spedali Civili	Valentina Zizioli	
MB	Monza	Ospedale San Gerardo	Andrea A. Lissoni	
MI	Milano	Istituto Europeo di Oncologia	Nicoletta Colombo *	
MI	Milano	Istituto Nazionale dei Tumori	Francesco Raspagliesi	
PD	Padova	Istituto Oncologico Veneto	Valentina Guarneri	
PI	Pisa	Ospedale Santa Chiara	Angiolo Gadducci	
TO	Torino	Ospedale Sant'Anna	Dionyssios Katsaros	

*MaNGO Principal Investigator

** Submission in Italy: ongoing